retatrutide glp-1 gip glucagon receptor agonist just had its biggest data year yet. In 2026, Eli Lilly's triple GLP-1/GIP/glucagon posted two major Phase 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight retatrutide - Diabetes In Control

Restless legs syndrome (often called restless leg syndrome or RLS) is a disorder that causes an overwhelming urge to move the legs, usually to alleviate unpleasant sensations

GLP-1 therapies reduced inflammatory markers and protected kidney function in animals and humans, including in the FLOW trial

GLP-1 26521434 (Diabetol Int

For context, bariatric surgery typically produces 25 to 30 percent total body weight loss

List of GLP-1 agonists How GLP-1 Agonists Work Differently from GLP-1/Glucagon-like Peptide-1

Zsrmj: Zsrmjbetegsghez vezethet, amely idvel mjelgtelensgg, mjzsugorr vlhat, vagy akr mjtltetst is szksgess tehet